BillionToOne, Inc. vs NATERA, INC., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where BLLN and NTRA diverge most: on operating margin, BLLN reads 16.4% and NTRA reads -13.4%; on net margin, BLLN reads 1.7% and NTRA reads -9.1%. The rest of the comparable metrics sit closer together. The bull and bear cases for each are in their full reports below.
| Metric | BLLN | NTRA |
|---|---|---|
| Price | $138.56 | $267.71 |
| Market cap | $7.3B | $37.9B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Growth | Growth |
| P/B | 14.53 | 21.35 |
| P/S | 25.40 | 15.15 |
| EV/EBITDA | 429.9 | — |
| Revenue growth | +100.6% | +36.4% |
| Gross margin | 73.0% | — |
| Operating margin | 16.4% | -13.4% |
| Net margin | 1.7% | -9.1% |
| Return on equity | 0.9% | -12.8% |
| Return on assets | 0.7% | -8.7% |
| Return on invested capital | 2.0% | -13.8% |
| FCF yield | 0.4% | 0.3% |
| Debt / equity | 0.18 | 0.05 |
| Current ratio | 10.92 | 2.96 |
| Altman Z (solvency) | 6.95 | 5.81 |
| Piotroski F (quality) | 5 / 9 | 4 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.